Outcome disparities in patients with atrial fibrillation based on insurance plan and educational attainment: a nationwide, multicenter and prospective cohort trial

Figures

• 

  Figure 1. Kaplan-Meier curve for all-cause mortality with 95% confidence limits. (A) Kaplan-Meier curve for all-cause mortality by insurance plans. (B) Kaplan-Meier curve for all-cause mortality by educational attainment. CSMBS, civil servant medical benefit scheme; NGS, non-government-based scheme; SSS, social-security scheme; UCS, universal coverage scheme.

• 

  Figure 2. Differences in adjusted restricted median survival time to all-cause mortality over a period of 36 months. The model was adjusted for of age, sex, educational attainment, insurance plan, types of anticoagulant, CHA2DS2VASc, and HASBLED scores. CAD, coronary artery disease; CHA2DS2-VASc, congestive heart failure, hypertension, age≥75 years, diabetes mellitus, stroke or transient ischaemic attack (TIA), vascular disease, age 65–74 years, sex category; CHF, congestive heart failure; CSMBS, civil servant medical benefit scheme; DOAC, direct oral anticoagulant; HASBLED, hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly (>65 years), drugs/alcohol concomitantly; NGS, non-government-based scheme; SSS, social-security scheme; UCS, universal coverage scheme; VKA, vitamin K antagonist.

• 

  Figure 3. Differences in adjusted restricted median survival time to ischaemic stroke over a period of 36 months. The model was adjusted for of age, sex, educational attainment, insurance plan, types of anticoagulant, CHA2DS2VASc and HASBLED scores. CAD, coronary artery disease; CHA2DS2VASc, congestive heart failure, hypertension, age≥75 years, diabetes mellitus, stroke or transient ischaemic attack (TIA), vascular disease, age 65–74 years, sex category; CHF, congestive heart failure; CSMBS, civil servant medical benefit scheme; DOAC, direct oral anticoagulant; HASBLED, hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly (>65 years), drugs/alcohol concomitantly; NGS, non-government-based scheme; SSS, social-security scheme; UCS, universal coverage scheme; VKA, vitamin K antagonist.

• 

  Figure 4. Differences in adjusted restricted median survival time to major bleeding over a period of 36 months. The model was adjusted for of age, sex, educational attainment, insurance plan, types of anticoagulant, CHA2DS2VASc and HASBLED scores. CAD, coronary artery disease; CHA2DS2VASc, congestive heart failure, hypertension, age≥75 years, diabetes mellitus, stroke or transient ischaemic attack (TIA), vascular disease, age 65–74 years, sex category; CHF, congestive heart failure; CSMBS, civil servant medical benefit scheme; DOAC, direct oral anticoagulant; HASBLED, hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly (>65 years), drugs/alcohol concomitantly; NGS, non-government-based scheme; SSS, social-security scheme; UCS, universal coverage scheme; VKA, vitamin K antagonist.